ICCM News and Press, IceCure Medical Ltd. From 07/25/22

IceCure Medical ( NASDAQ: ICCM ) said on Monday it had submitted regulatory filing with the Canadian governmental agency for approval of its cancer killing device, ProSense System and its cryoprobes, to treat a number of cancers, including breast cancer, lung cancer, renal...

IceCure Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors PR Newswire Canadian hospitals and health care providers have expressed strong interest in ProSense® ...

Former Itamar Medical CEO & President Gilad Glick Joins IceCure Medical as a Strategic Advisor for Global Go-To-Market Operations Former Itamar Medical CEO & President Gilad Glick Joins IceCure Medical as a Strategic Advisor for Global Go-To-Market Operations PR News...

IceCure's ProSense® Featured at SIR 2022 Annual Meeting in Breast Cancer Cryoablation Categorical Course PR Newswire Strong interest in ProSense from potential customers and distributors spurred by categorical course and Shanghai Medtronic deal CAESA...

IceCure Medical, Shanghai Medtronic & Turing Medical Sign Distribution Agreement in Mainland China IceCure Medical, Shanghai Medtronic & Turing Medical Sign Distribution Agreement in Mainland China PR Newswire Shanghai Medtronic to exclusively distribut...

IceCure Medical (NASDAQ:ICCM) on Thursday said its Brazilian distributor KTRFIOS had submitted a regulatory filing to the country's drug regulator for approval of ICCM's ProSense System in several indications. ICCM's ProSense System destroys tumors by freezing, providing an alternat...

IceCure Medical's ProSense® Cryoablation System Submitted for Regulatory Approval in Brazil PR Newswire Regulatory filing submitted by KTRFIOS, IceCure's distributor in Brazil Filing includes breast and other cancers, benign tumors, palliative ...

IceCure Medical Ltd. (ICCM) Q1 2022 Earnings Conference Call May 18, 2022 8:30 AM ET Company Participants Eyal Shamir - Chief Executive Officer Ronen Tsimerman - Chief Financial Officer and Chief Operating Officer Richard Fine - Investigator of ICE3 Clinical Trial Conference Call Participants...

IceCure Medical press release (NASDAQ:ICCM): Q1 GAAP EPS of -$0.12. Revenue of $0.75M (-47.6% Y/Y). As of March 31, 2022, the Company had cash and cash equivalents of approximately $22.4 million, compared with approximately $25.6 million as of December 31, 2021. For further details see: ...

IceCure Medical Reports First Quarter 2022 Financial Results and Operational Highlights PR Newswire Conference call scheduled for 8:30 am ET today hosted by management with guest Dr. Richard Fine Increased commercial activity in the U.S. and glo...